<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140615018091N10</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-15</date_registration>
      <primary_sponsor>Bandare-abbas University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effect of adding morphine or pethidine to bupivacaine into the spinal space while producing numbness for cesarean section surgery on post-operative pain of pregnant women with a pregnancy age of over 37 weeks</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of adding intrathecal morphine or pethidine to bupivacaine in spinal anesthesia during cesarean section surgery on post-operative pain of pregnant women with a gestational age of over 37 weeks</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-06-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44270</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation software will be used to design a permuted block randomization table with a 1:1 allocation. Block sizes of 2, 4 and 6 will be used. According to the size of each block concealed opaque sequentially numbered envelopes containing the either assigned group A or B will be drawn. Allocation concealment and blinding to the block sizes will be applied to the primary anesthesiologist responsible for applying the study protocol, Blinding description: The following group of people involved in the blinding is: The participating parturients involved in the study will not be aware of the type of drug being injected intrathecally. However, written informed consent will be obtained from the participants. A second anesthesiologist who is participating in the trial but is not in charge of patient care will be responsible for collecting data in the operating room and will be blinded to the designation group of the pregnant participants and medications prescribed in the protocol. The medical student responsible for collecting the results of the study will also be blinded to the inclusion of parturients in the groups and the drugs prescribed in the protocol.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: pregnancy. Condition 2: spinal anesthesia. Condition 3: hemodynamic changes. Condition 4: postoperative pain.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group parturients while being in the sitting position, a Quincke needle No. 25 will be inserted into the lumbar space 3-4 or 4-5 and a total volume of 3 ml of a solution containing 12 mg of bupivacaine (0.5 %) )BUPIVACAINE MYLAN 20MG/4ML, Haupt Pharma Livron S.A.S. CO.)  with 200 micrograms of morphine sulfate (Alborz Daru CO.) will be injected into the subarachnoid spaces. Intervention 2: ّThe second intervention group parturients while being in the sitting position, a Quincke needle No. 25 will be inserted into the lumbar space 3-4 or 4-5 and a total volume of 3 ml of a solution containing 12 mg of bupivacaine (0.5 %) )BUPIVACAINE MYLAN 20MG/4ML, Haupt Pharma Livron S.A.S CO.)  with 20 mg of pethidine (Caspian Tamin CO.) will be injected into the subarachnoid spaces.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected deidentified IPD will be available.

When:
Starting 12 months after publication.

To whom:
This will be only made available for people working in academic institutions.

Conditions:
The requests for review will be answered according to the policies provided by the body of regulations that is stated by the Vice-chancellor of research of Hormozgan University of medical sciences.

Where to obtain:
Requests can be sent to Dr. Abbas Moellemy at moallemyaln@yahoo.com

How to obtain:
The request for deidentified participant data review will be evaluated by the anesthesiology research center vice-chancellor and referred to the Hormozgan university vice-chancellor for assessing the eligibility of the requesting party this may take 1-3 months.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereydoon Fekrat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology, Intensive care and Pain control research center, Shahid Mohammadi Hospital, Islamic Republic Blvd., Bandar Abbas</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7919915519</zip>
        <telephone>+98 76 3334 5009</telephone>
        <email>fereydoonfekrat@yahoo.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abbas Moallemy</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Joomhoori Islami Blv., Shahid Mohammadi Hospital, Bandar Abbas, Iran</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7919915519</zip>
        <telephone>+98 76 3334 5009</telephone>
        <email>moallemyaln@yahoo.com</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18-50
Gestational age of over 37 weeks
American Society of Anesthesiologists physical status classes I and II
Candidate for a cesarean section surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Emergency cesarean section
Limitations for applying regional block,
Valvular heart disease
A history of allergy to the target drugs
Addicts
Alcoholics
Preeclampsia
Diabetes
Unwillingness to take part in the research</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group parturients while being in the sitting position, a Quincke needle No. 25 will be inserted into the lumbar space 3-4 or 4-5 and a total volume of 3 ml of a solution containing 12 mg of bupivacaine (0.5 %) )BUPIVACAINE MYLAN 20MG/4ML, Haupt Pharma Livron S.A.S. CO.)  with 200 micrograms of morphine sulfate (Alborz Daru CO.) will be injected into the subarachnoid spaces.</i_keyword>
      <i_keyword>ّThe second intervention group parturients while being in the sitting position, a Quincke needle No. 25 will be inserted into the lumbar space 3-4 or 4-5 and a total volume of 3 ml of a solution containing 12 mg of bupivacaine (0.5 %) )BUPIVACAINE MYLAN 20MG/4ML, Haupt Pharma Livron S.A.S CO.)  with 20 mg of pethidine (Caspian Tamin CO.) will be injected into the subarachnoid spaces.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of post surgical pain. Timepoint: 1st, 4th and 24th hours after surgery. Method of measurement: Numeric Rating Scale.</prim_outcome>
      <prim_outcome>The first demand for analgesia. Timepoint: after the surgery. Method of measurement: minutes after the surgery.</prim_outcome>
      <prim_outcome>Dose of the analgesic. Timepoint: after the surgery. Method of measurement: the number of diclofenac suppositories (100 mg) applied.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Nausea and vomiting. Timepoint: 1st, 4th and 24th hours after surgery. Method of measurement: Quantitative frequency will be recorded on questionnaire.</sec_outcome>
      <sec_outcome>Itching. Timepoint: During surgery and in the 1st, 4th and 24th after the surgery. Method of measurement: Quantitative frequency will be recorded on questionnaire.</sec_outcome>
      <sec_outcome>Blood pressure (systolic and diastolic). Timepoint: The first 10 minutes will be measured every 3 minutes and then every 5 minutes till the end of the surgery. Post-operatively at the 1st, 4th and 24th hours. Method of measurement: Non-invasive blood pressure device.</sec_outcome>
      <sec_outcome>Respiratory rate. Timepoint: Within the first 10 minutes every 3 minutes and then every 5 minutes till the end of the surgery. Post-operatively at the 1st, 4th and 24th hours. Method of measurement: Respiration monitoring by using Electrocardiograph device.</sec_outcome>
      <sec_outcome>Sedation condition. Timepoint: During the surgery as well as in the 1st, 4th and 24th hours after surgery. Method of measurement: Ramsey Sedation Scale.</sec_outcome>
      <sec_outcome>Assessment for infants health condition after delivery. Timepoint: 1st and 5th minutes of birth. Method of measurement: Apgar score.</sec_outcome>
      <sec_outcome>Shivering. Timepoint: During the surgery and in the 1st, hours after surgery. Method of measurement: Quantitative frequency recorded on questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bandare-abbas University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-11-26</approval_date>
        <contact_name>Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>Anesthesiology Research Center, Shahid Mohammadi Hospital, Islamic Republic Blvd. Bandar Abbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
